Business Context and Reporting Period
Company: LeMaitre Vascular, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 11, 2019
Event: Entry into a Material Definitive Agreement and Completion of Acquisition of Assets.
On October 11, 2019, LeMaitre Vascular, Inc. consummated the acquisition of the biologic patch business (CardioCel, CardioCel 3D, CardioCel Neo, VascuCel, and VascuCel 3D) from Admedus Ltd and certain subsidiaries. The transaction included an Asset Purchase Agreement, a License Agreement for necessary technology, and a Transition Services Agreement for product supply up to three years.
Key Financial Metrics and Transaction Terms
The filing details the consideration paid for the acquisition but does not provide the Company's standalone revenue, profit, cash flow, or margin data for the reporting period.
- Total Cash Consideration: $15,515,000
- Payment Schedule:
- $14,175,000 paid on the Closing Date (October 11, 2019).
- $670,000 payable one year following the Closing Date.
- $670,000 payable three years following the Closing Date.
- Contingent Consideration (Earn-outs): Up to $8,450,000 based on regulatory certification, sales milestones, shelf-life extension, and delivery of financial statements.
- Assets Acquired: Tangible assets, intellectual property, registrations, inventory, data records, and goodwill.
Material Changes and Strategic Impact
This acquisition represents a material expansion of LeMaitre's product portfolio into cardiac and vascular repair patches. The transaction introduces new revenue streams subject to performance milestones and regulatory approvals. The Company has agreed to non-compete restrictions regarding the manufacture of these products for other medical device companies and has granted Admedus a right of first refusal to repurchase the business if a third-party offer is received before December 31, 2020.
Guidance, Outlook, and Risks
Outlook and Milestones: Future payments are contingent upon specific operational and regulatory achievements, including:
- Receipt of Conformité Européenne (CE) mark certification under the European Medical Devices Regulation ($2,000,000).
- Sales targets of $15M-$20M in the first 12 months and $22.5M-$30M in the second 12 months.
- Extension of product shelf-life from 36 to 60 months in the United States.
Risks and Contingencies:
- Regulatory Risk: A significant portion of the contingent consideration depends on obtaining CE mark certification.
- Operational Risk: The Company relies on Admedus for product supply for up to three years under the transition services agreement.
- Financial Reporting: Pro forma financial information and financial statements of the acquired business are not included in this filing and are expected to be filed within 71 days.
Investor Verification Checklist
- Verify the status of the CE mark certification for the acquired products to assess the likelihood of the $2,000,000 contingent payment.
- Monitor the Company's upcoming Form 10-K (due within 71 days) for the pro forma financial information and audited financial statements of the acquired business.
- Review the transition services agreement terms to understand the duration and cost implications of relying on Admedus for product supply.
- Track sales performance of the acquired products against the $15M and $20M thresholds to evaluate potential earn-out liabilities.